Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Japanese Subjects with Advanced Solid Tumors or Lymphomas

Next Previous
X
Search
Trial Profile

A phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Japanese Subjects with Advanced Solid Tumors or Lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milademetan (Primary)
  • Indications Advanced breast cancer; Gallbladder cancer; Gastric cancer; Leiomyosarcoma; Liposarcoma; Malignant thymoma; Parotid cancer; Pharyngeal neoplasms; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 01 Jun 2021 Results published in the Cancer Science
    • 01 Jun 2021 Status changed to completed , according to Results published in the Cancer Science
    • 27 Mar 2018 Planned End Date changed from 31 Mar 2017 to 31 Mar 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top